Engineered immune cells take on hard-to-treat blood cancers in early trial
NCT ID NCT04684563
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This early-phase study tests a new cell therapy called huCART19-IL18 for people with CD19-positive blood cancers (like some leukemias and lymphomas) that have relapsed or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better target and attack cancer cells. The main goals are to check safety and find the best dose, with about 72 participants expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.